FOSINOPRIL SODIUM (fosinopril sodium) by Signatur Biosciences is clinical pharmacology mechanism of action in animals and humans, fosinopril sodium is hydrolyzed by esterases to the pharmacologically active form, fosinoprilat, a specific competitive inhibitor of angiotensin-converting enzyme (ace). Approved for hypertension, the management of heart failure, without digitalis (see ). First approved in 2004.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Mechanism of Action In animals and humans, fosinopril sodium is hydrolyzed by esterases to the pharmacologically active form, fosinoprilat, a specific competitive inhibitor of angiotensin-converting enzyme (ACE). ACE is a peptidyl dipeptidase that catalyzes the conversion of…
Worked on FOSINOPRIL SODIUM at Signatur Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.